Enveric Biosciences, a leading psychedelics biotech company, is making waves in the field with its innovative approach to treating mental health conditions. At the 7th Neuropsychiatric Drug Summit, the company presented compelling research on its lead compound, EB-003, a non-hallucinogenic analog of the psychedelic substance N,N-Dimethyltryptamine (DMT). This research sheds light on EB-003’s potential as a therapeutic agent for anxiety and depression.
EB-003 is designed to harness the therapeutic benefits of DMT while eliminating the hallucinogenic effects. The company previously announced positive preclinical results demonstrating that oral administration of EB-003 provides significant brain exposure in rodent models at potentially therapeutic doses. The research presented at the summit further reinforces this promise.
The presentation, titled “Non-hallucinogenic and neuropathogenic DMT analog imparts positive behavioral outcomes in mice,” delved into the meticulous design and development of EB-003. Researchers focused on creating a non-hallucinogenic derivative of DMT that could effectively target neuropsychiatric disorders. The research showed that EB-003 achieved positive behavioral outcomes in two mouse models, demonstrating its potential to reduce anxiety and depression.
One of the key aspects of the study involved examining the head twitch response in rodents, a behavioral indicator of hallucinogenic effects in humans. While DMT showed the typical psychedelic effects in this test, EB-003 displayed a complete absence of such effects. This finding reinforces EB-003’s unique profile as a non-hallucinogenic therapeutic.
Joseph Tucker, Ph.D., CEO of Enveric, explained the potential mechanisms behind the therapeutic effects: “The underlying mechanism of how psychedelics work to treat psychiatric conditions is hotly contested, but much of the leading scientific evidence points to the induction of neuroplasticity, essentially enabling the brain to rewire itself. The capability to cause this, called neuroplastogenicity, is found in the psychedelics currently in late-stage clinical trials and, as demonstrated in the poster being presented today, in EB-003.”
Enveric is now looking towards the future, with plans to file an Investigational New Drug (IND) application for EB-003 in the third quarter of 2025 and initiate clinical development by the end of the same year. This promising research holds the potential to revolutionize the treatment of anxiety and depression, offering patients a new and effective therapeutic option. “While all of these results need to be replicated in humans, we are very encouraged by the EB-003 results, and eagerly look forward to the human clinical trials of EB-003 that are anticipated to begin later in 2025.” said Tucker, expressing the company’s enthusiasm for the next stage of development.
The research presented at the Neuropsychiatric Drug Summit marks a significant step forward in Enveric Biosciences’ mission to develop innovative treatments for mental health disorders. With its focus on creating non-hallucinogenic DMT analogs, Enveric is paving the way for a new era of psychedelic-inspired therapies that have the potential to transform the lives of millions.
